RYTM Live signals | Maximize Profits with Getagraph.com

BUY 101932 min ago

@ $49.81

Issued: 14 Feb 2024 @ 15:43

Return: -24.78%

Previous signal: Feb 13 - 10:40

Previous signal: Sell

Return: 1.67 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:35):

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity...

Stats
Today's Volume	83 862.00
Average Volume	580 864
Market Cap	2.25B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-2.12 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.71
ATR14	$0.0560 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Mazabraud Yann	Sell	10 375	Common Stock
2024-04-14	Mazabraud Yann	Sell	10 375	Restricted Stock Units
2024-04-15	Mazabraud Yann	Buy	10 000	Restricted Stock Units
2024-04-15	Mazabraud Yann	Buy	8 905	Restricted Stock Units
2024-04-15	Mazabraud Yann	Sell	6 874	Restricted Stock Units

INSIDER POWER
38.89
Last 100 transactions
Buy: 1 143 191 \| Sell: 502 628

Volume Correlation

Long: 0.53 (weak)

Short: -0.20 (neutral)

Signal:(39.789) Neutral

Rhythm Pharmaceuticals Correlation

10 Most Positive Correlations
ENTA	0.875
AVDX	0.86
FNWD	0.855
FYBR	0.853
CNXC	0.842
SLVO	0.832
CNDT	0.825
ALKT	0.824
ATHA	0.819
ASMB	0.814

10 Most Negative Correlations
TRKA	-0.848
PPBT	-0.837
TCRX	-0.827
LMNL	-0.815
SNCR	-0.813
LNTH	-0.812
WAVD	-0.808
MVBF	-0.807
VEDU	-0.804
VTNR	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rhythm Pharmaceuticals Correlation - Currency/Commodity

-0.66
( moderate negative )

-0.77
( moderate negative )

0.00
( neutral )

-0.63
( weak negative )

-0.34
( neutral )

-0.27
( neutral )

Rhythm Pharmaceuticals Financials

Annual	2023
Revenue:	$77.43M
Gross Profit:	$68.13M (87.99 %)
EPS:	$-3.20

Q4	2023
Revenue:	$24.23M
Gross Profit:	$21.00M (86.66 %)
EPS:	$-0.700

Q3	2023
Revenue:	$22.50M
Gross Profit:	$20.09M (89.28 %)
EPS:	$-0.760

Q2	2023
Revenue:	$19.22M
Gross Profit:	$16.99M (88.37 %)
EPS:	$-0.820

Financial Reports:

No articles found.

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.